Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562970 | 1.00 | MAPT (1.00) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL22309920 | 0.85 | ALDH1A1 (1.00) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8591336 | 0.85 | MAPT (1.00) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL8591331 | 0.85 | MAPT (1.00) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL16077770 | 0.85 | MAPT (1.00) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10453546 | 0.83 | MAPT (0.70) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL14614903 | 0.83 | MAPT (0.73) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL10453548 | 0.83 | MAPT (0.70) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL31307214 | 0.82 | ALDH1A1 (0.71) | MAPTALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL13374840 | 0.81 | ALDH1A1 (0.71) | MAPTALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2353593-B1 | Non-nucleoside reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2353593-A1 | Non-nucleoside reverse transcriptase inhibitors | Ardea Biosciences, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2353593-A1 | Non-nucleoside reverse transcriptase inhibitors | Ardea Biosciences, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-1545483-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1545483-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-1545483-A4 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | INTRABIOTICS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1545483-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Ribapharm Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004030611-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RIBAPHARM INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249131-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, TYMP, RNGTT | MAPT 702/4885ALDH1A1 271/4885LMNA 1811/4885 |
| US-20060135556-A1 | Non-nucleoside reverse transcriptase inhibitors | POLRMT, TYMP, RNGTT | MAPT 702/4885ALDH1A1 271/4885LMNA 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.